Patents by Inventor Sahana BOSE

Sahana BOSE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20210145978
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Inventors: Shweta Singh, Jennifer Hope Richardson, Laura Patterson Serwer, Jonathan Alexander Terret, Susan E. Morgan-Lappe, Tracy Henriques, Sherry L. Ralston, Marvin Robert Leanna, Ilari Badagnani, Sahana Bose
  • ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20190111150
    Abstract: The invention relates generally to conjugated activatable antibodies that bind CD71 in their active form and methods of making and using these anti-CD71 conjugated activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Inventors: Shweta SINGH, Jennifer Hope RICHARDSON, Laura Patterson SERWER, Jonathan Alexander TERRETT, Susan E. MORGAN-LAPPE, Tracy HENRIQUES, Sherry L. RALSTON, Marvin Robert LEANNA, Ilaria BADAGNANI, Sahana BOSE
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20160272703
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 22, 2016
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • IMMUNOBINDERS DIRECTED AGAINST SCLEROSTIN
    Publication number: 20150266977
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Application
    Filed: February 18, 2015
    Publication date: September 24, 2015
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yulia Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20150111251
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: September 25, 2014
    Publication date: April 23, 2015
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • Immunobinders directed against sclerostin
    Patent number: 8999331
    Abstract: Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: April 7, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Alexander Ivanov, Wendy Waegell, Yuliya Kutskova, John Memmott, Lorenzo Benatuil, Jacqueline Bixby, Emma Fung, Sahana Bose, Alyssa Brito
  • TNF-? binding proteins
    Patent number: 8877194
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 4, 2014
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Carrie L. Goodreau, Sahana Bose, Achim Moeller, Tariq Ghayur
  • TNF-ALPHA BINDING PROTEINS
    Publication number: 20120230911
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: December 8, 2011
    Publication date: September 13, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Chung-ming HSIEH, Carrie L. GOOGREAU, Sahana BOSE, Achim MOELLER, Tariq GHAYUR